Edgewise Therapeutics (EWTX) Gets a Buy From RBC Capital
RBC Capital Maintains Outperform on Edgewise Therapeutics, Raises Price Target to $32
Edgewise Therapeutics Analyst Ratings
Royal Bank of Canada: Maintaining the Edgewise Therapeutics (EWTX.US) rating, adjusted from superior to superior market rating, and adjusted the target price from $28.00 to $32.00.
Analysts Are Bullish on These Healthcare Stocks: Bausch + Lomb Corporation (BLCO), Edgewise Therapeutics (EWTX)
Truist Securities: Maintains Edgwise Therapeutics (EWTX.US) rating, adjusted from buy to buy rating, and adjusted target price from $25.00 to $25.00.
Edgewise Therapeutics Analyst Ratings
Truist Securities Maintains Buy on Edgewise Therapeutics, Maintains $25 Price Target
Analysts Offer Insights on Healthcare Companies: Edgewise Therapeutics (EWTX), Healthequity (HQY) and Nuvation Bio (NUVB)
Wedbush: The Edgewise Therapeutics (EWTX.US) rating was reaffirmed and adjusted from superior to superior market rating, with a target price of $26.00.
Edgewise Therapeutics Analyst Ratings
Wedbush Reiterates Outperform on Edgewise Therapeutics, Maintains $26 Price Target
Edgewise Therapeutics (EWTX) Receives a Buy From Wedbush
Edgewise Therapeutics Analyst Ratings
RBC Capital Sticks to Their Buy Rating for Edgewise Therapeutics (EWTX)
Edgewise Therapeutics Analyst Ratings
Truist Financial Remains a Buy on Edgewise Therapeutics (EWTX)
Buy Rating Affirmed for Edgewise Therapeutics Amid Anticipated Positive Trial Outcomes and Strategic FDA Alignment
Analysts Are Bullish on These Healthcare Stocks: Edgewise Therapeutics (EWTX), Bicycle Therapeutics (BCYC)
Analysts Offer Insights on Healthcare Companies: Doximity (DOCS), RayzeBio, Inc. (RYZB) and Edgewise Therapeutics (EWTX)
No Data